CN102526539B - Traditional Chinese medicinal compound for treating idiopatic thrombocytopenic purpura (ITP) - Google Patents
Traditional Chinese medicinal compound for treating idiopatic thrombocytopenic purpura (ITP) Download PDFInfo
- Publication number
- CN102526539B CN102526539B CN201210072570.2A CN201210072570A CN102526539B CN 102526539 B CN102526539 B CN 102526539B CN 201210072570 A CN201210072570 A CN 201210072570A CN 102526539 B CN102526539 B CN 102526539B
- Authority
- CN
- China
- Prior art keywords
- radix
- itp
- grams
- chinese medicine
- thrombocytopenic purpura
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides a Chinese medicinal compound for treating idiopatic thrombocytopenic purpura (ITP). The Chinese medicinal compound comprises the following medicines by weight: 5 to 40 grams of heterophylly falsestarwort root, 1 to 30 grams of rhubarb, 1 to 35 grams of szechuan lovage rhizome, 1 to 37 grams of cicada slough, 1 to 45 grams of sophora flower, 2 to 50 grams of rehmannia root, 3 to 45 grams of white paeony root, 1 to 30 grams of lalang grass rhizome, 5 to 50 grams of donkey-hide gelatin, 1 to 36 grams of Chinese angelica, 1 to 33 grams of divaricate saposhnikovia root and 2 to 35 grams of liquoric root. The Chinese medicinal compound has a definite treatment effect on ITP, is safe and few in side effects and has a bright market prospect.
Description
Technical field
The invention belongs to tcm field, be specifically related to a kind of Chinese medicine for the treatment of immunologic thrombocytopenic purpura.
Background technology
Immunologic thrombocytopenic purpura (Idiopathic Thrombocytopenic Purpura, ITP) be clinical common hemorrhage, with peripheral blood thrombocytopenia, it is feature that bone marrow megakaryocyte increases companion's dysmaturity, is the hemorrhage syndrome of autoimmunity.The maximum harm of primary disease is to cause coagulation disorders, the mucocutaneous Repeated Hemorrhage of the lighter, and obstinate causes anemia, and serious appearance menorrhagia, even merges intracranial hemorrhage, once there is threat to life.
Along with raising China's new discovery in recent years patient of diagnosis is increase trend.This disease sickness rate according to statistics, America and Europe is 6～11,/10 ten thousand populations, and Japan is 16.7/10 ten thousand populations, and patients with chronic idiopathic thrombocytopenlc purpura is mainly seen between adult 20～50 years old, and gender's ratio is 1: 3.Over nearly one, 20 year, modern medicine changes without essence the diagnoses and treatment of ITP, treatment ITP is mainly used glucocorticoid and splenectomy, although can make some patients were obtain clinical remission, but relapse rate is higher, often because platelet counts can not maintain safety range, need further to adopt the treatment measures such as immunosuppressant, androgen, bio-modification agent to maintain platelet counts in normal range, to reduce mortality rate.Can life-time service said medicine can bring and treat relevant series of problems, as not obvious in curative effect, relapse rate is high, organ injury, biochemical indicator abnormal and medical fee raises up etc.
Therefore find even more ideal medicine effective, that side reaction is few and become current research emphasis.Compare Chinese medicine with Western medicine and shown wide prospect in this field for the treatment of.Chinese medicine has obvious advantage in treatment aspect immunologic thrombocytopenic purpura, although it is comparatively slow with respect to hormone to promote the speed of platelet counts, late result is better, and can Reusability, without obvious adverse reaction.
Modern medicine is sent out speckle by the deficiency of YIN and is divided into thrombocytopenic purpura (comprising constitutional and Secondary cases) and anaphylactoid purpura two classes.From clinical characters, anaphylactoid purpura is more common in going out blood disorder, belonging to YANG macule scope more of " bleeding due to blood-heat ", controls clinically and take clearing away heat and cooling blood, promoting blood circulation and detoxication as main.Thrombocytopenic purpura mostly be the hepatic and renal YIN deficiency, spleen lung qi weak due to, or insufficiency of kidney-YANG every sun in outside, or deficiency of the kidney yin, water loses heated, blood is robbed, or insufficiency of the spleenly can not take the photograph blood, or deficiency of the liver can not make so by store blood, take in a word weakened body resistance as main.The hepatic and renal YIN deficiency, spleen lung qi are weak, the deficiency of YIN is hot vehement, and blood loses quiet " eruption of YIN syndrome ", therefore with the moon of nourishing the liver and kidney, the gas of strengthening spleen and lung, slightly helps the product of cooling blood for hemostasis, and the cloudy multiple empty positive intension of Liver and kidney, spleen lung qi fills that gas cloudy two is multiple, and blood network is quiet, and all cards are from pacifying.
The present invention be take Chinese medicine the syndrome of ITP comprehensive observing is to basis, the modern medicine of take is point of penetration to the understanding of ITP, from yin asthenia generating intrinsic heat, set forth one's views, think deficiency of the liver and kindey, deficiency of YIN heat is vehement is the main pathogenesis in ITP generation and evolution, propose nourishing YIN and clearing away heat, benefiting QI and nourishing blood is the basic principle for the treatment of ITP, has solid clinical theory and practice basis.
The Chinese medicine research worker of seminar of the present invention, through clinical research in nearly 40 years, adopts method dialectical and that differential diagnosis of diseases combines, and the ITP that treats thousands of examples suffers from, and receives significant curative effect.Clinical manifestation in conjunction with ITP patient, find that ITP clinical disease is how relevant with yin asthenia generating intrinsic heat, and ITP pathogenesis is proposed to unique opinion, in the clinical research in early stage, find to there is original curative effect on nourishing YIN and clearing away heat ruling by law treatment ITP, obtained gratifying effect and good economic benefit and social benefit.
Through update search, though there are some kind listings of direct or indirect treatment blood deficiency (anemia), but be specifically designed to the Chinese patent medicine of ITP seldom, " XUEKANG KOUFUYE " (this product is Chinese medicine extract) of 2000 editions one of the main wherein < < Pharmacopoeia of People's Republic of China > > of the at present clinical ITP of being mainly used in treatment, " weixuening electuary ", " the U.S. peace of blood capsule ".Though these kinds play a role in the control to primary disease, all there is not strong this unfavorable factor of specific aim.Comprehensive document in recent years, the ITP cause of disease can be summarized as diseases caused by exogenous pathogenic factor and internal injury; Pathogenesis can be summarized as: in (1) evil poison, disturb (2) QI failing to control blood, (3) hyperactivity of fire caused by deficiency of YIN, (4) obstruction of collaterals by blood stasis.Above-mentioned each kind is this pathogenic characteristic of complete reaction not all.
Though the traditional Chinese medical science is without this name of disease of idiopathic thrombocytopenic purpura, clinical in characteristicness such as various hemorrhage and ecchymosis petechias from ITP, thinks that it belongs to " blood disorder " category of the traditional Chinese medical science.From chronic ITP clinical manifestation, common purpura is flickering, touching more not and the deficiency of spleen-QI performance such as fatigue and weak, anorexia.For this reason, having proposed yin asthenia generating intrinsic heat is the basic of ITP morbidity, recognizes the hepatic and renal YIN deficiency, spleen lung qi is weak, the deficiency of YIN is hot vehement, and it is the main pathogenic of primary disease that blood loses quiet.Therefore establish " nourishing YIN and clearing away heat " method for the treatment of.Apply in prescription treatment ITP patient's of the present invention clinical research in early stage, according to Second China National hematology academic conference, formulate efficacy assessment standard: effective, effective, progressive, invalid.100 routine ITP patients have been carried out to observation of curative effect in more detail, and result shows, obvious effective rate 65%, effective percentage 91.67%.Through Long-term Clinical Observation, find this obviously relief of symptoms, and relapse rate is low, long-term taking has no untoward reaction to human body.
Through clinical observation and the pharmacodynamic study of many decades, show that prescription treatment ITP patient of the present invention receives comparatively satisfied curative effect., till the present, there is not yet this sick Chinese patent medicine listing of special for treating, succeeding in developing of this medicine will be filled up this blank, and treatment by Chinese herbs ITP determined curative effect, safety, few side effects, market prospect is extremely wide, once put on market, will obtain good economic benefit and social benefit.Comprehensive statistics both domestic and external, calculate by ten thousand/population, and will there be tens0000 patients in the whole nation, need spend 1000 yuan of expensess for medicine a course for the treatment of, calculate, and year use amount is more than 100,000,000 yuan, and market potential is huge.
Summary of the invention
The object of this invention is to provide a kind of Chinese medicine for the treatment of immunologic thrombocytopenic purpura, this treatment by Chinese herbs ITP determined curative effect, safety, few side effects, market prospect is extremely wide.
The invention provides a kind of Chinese medicine for the treatment of immunologic thrombocytopenic purpura, this ingredients is as follows: Radix Pseudostellariae 5-40g, Radix Et Rhizoma Rhei 1-30g, Rhizoma Chuanxiong 1-35g, Periostracum Cicadae 1-37g, Flos Sophorae 1-45g, Radix Rehmanniae 2-50g, Radix Paeoniae Alba 3-45g, Rhizoma Imperatae 1-30g, Colla Corii Asini 5-50g, Radix Angelicae Sinensis 1-36g, Radix Saposhnikoviae 1-33g, Radix Glycyrrhizae 2-35g.
The Chinese medicine for the treatment of immunologic thrombocytopenic purpura provided by the invention, this ingredients is preferably as follows: this ingredients is as follows: Radix Pseudostellariae 10-30g, Radix Et Rhizoma Rhei 5-20g, Rhizoma Chuanxiong 5-20g, Periostracum Cicadae 6-19g, Flos Sophorae 8-20g, Radix Rehmanniae 10-30g, Radix Paeoniae Alba 13-27g, Rhizoma Imperatae 10-25g, Colla Corii Asini 15-30g, Radix Angelicae Sinensis 5-20g, Radix Saposhnikoviae 5-15g, Radix Glycyrrhizae 10-25g.
The Chinese medicine compound for the treatment of immunologic thrombocytopenic purpura provided by the invention, this ingredients is preferably as follows: this ingredients is as follows: Radix Pseudostellariae 20g, Radix Et Rhizoma Rhei 10g, Rhizoma Chuanxiong 10g, Periostracum Cicadae 10g, Flos Sophorae 15g, Radix Rehmanniae 20g, Radix Paeoniae Alba 20g, Rhizoma Imperatae 15g, Colla Corii Asini 25g, Radix Angelicae Sinensis 10g, Radix Saposhnikoviae 10g, Radix Glycyrrhizae 15g.
The Chinese medicine for the treatment of immunologic thrombocytopenic purpura provided by the invention, described Radix Et Rhizoma Rhei is processed with wine processed product.
The effect of the Chinese medicine for the treatment of immunologic thrombocytopenic purpura provided by the invention: dispelling wind removing toxic substances, cooling blood for hemostasis.
Curing mainly of the Chinese medicine for the treatment of immunologic thrombocytopenic purpura provided by the invention: disturb purpura due to knot in blood stasis in evil poison.Subcutaneous petechia ecchymosis, or epistaxis, have blood in stool, hematuria etc., body of the tongue is dim or have a petechia, thready and hesitant pulse.
The side of the Chinese medicine for the treatment of immunologic thrombocytopenic purpura provided by the invention separates: Radix Saposhnikoviae, the removing toxic substances of Periostracum Cicadae dispelling wind are monarch drug altogether.The Radix Et Rhizoma Rhei blood stasis dispelling that purges heat, the Radix Rehmanniae, Rhizoma Imperatae nourishing YIN and clearing away heat, cooling blood for hemostasis, is ministerial drug altogether.Rhizoma Chuanxiong, Radix Angelicae Sinensis, Radix Paeoniae Alba nourishing and enriching blood, Colla Corii Asini, Herba Agrimoniae nourishing blood and hemoslasis, Radix Pseudostellariae, Radix Glycyrrhizae and middle tonify deficiency, be adjuvant drug altogether.Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription, holds concurrently as making medicine.All medicines share, long memorial wind removing toxic substances altogether, and the merit of cooling blood for hemostasis, evil poison is loose, and blood stasis disappears, purpura spontaneous recovery.
Immunologic thrombocytopenic purpura (ITP) is common clinically hemorrhagic, autoimmune disease, and with periphery thrombocytopenia, megakaryocytic hyperplasia of bone marrow companion dysmaturity is feature.Rising year by year along with ITP sickness rate, about the clinical and basic research of ITP can confirm to a certain extent the generation of ITP and the change of bone marrow megakaryocyte closely related, and the propagation of bone marrow megakaryocyte, differentiation, maturation until hematoblastic production process by complicated cytokine network, regulated and controled.Regulate cytokine IL-3, IL-6, IL-11, TGF-β 1, the TPO effect in ITP morbidity of megakaryocytopoiesis, for Rational clinical use provides experimental basis.
IL-3 is important hemopoietic regulatory factor, is the main component of immune system hemopoietic system, and hematopoietic cell especially megalokaryocyte is had to important regulating and controlling effect.The mechanism of IL-3 increased platelets counts is by acting on early stage hemopoietic progenitor cell, promote its propagation, and promote the differentiation of hemopoietic progenitor cell with kit-ligand together with differentiation factor in late period (as erythropoietin, granulocyte colony-stimulating factor, M-CSF etc.), thereby finally promote hematoblastic generation.
IL-6 promotes megakaryocytopoiesis and generates a hematoblastic key factor have the effect that promotes that macronucleus precursor colony forms, can stimulating megakaryocyte DNA albumen synthetic, and have the effect that promotes the ripe and platelet release of megakaryocyte proliferation.IL-6 raises, activating immune system, stimulate the differentiation of B cell, the generation of platelet-associated antibody is increased, cause hematoblastic destruction to be increased, and antiplatelet antibody in serum is destroying the hematoblastic while, this antibody can stimulate bone marrow megakaryocyte compensatory hypertrophy, to increase the platelet counts in circulation.Clinical ITP patients serum IL-6 level is detected, find that compared with normal obviously raises, treatment declines after alleviating, and during recurrence, raises once again, shows the state of an illness weight of ITP of IL-6 height.This result also confirms that blood serum IL-6 has practical relation with ITP really, therefore detection blood serum IL-6 can be research ITP cause and onset of disease mechanism, provides theoretical foundation, meanwhile, contributes to the clinical observation state of an illness, judgement curative effect, estimation prognosis.
IL-11 is a kind of cytokine with several functions of being secreted by hematopoieticmicroenviron-ment marrow stromal cell, also be important hemopoietic regulatory factor, in recent years as promoting the thrombopoietic factor extremely to pay attention to, it can be combined on the memebrane protein of extracellular matrix and stromal cell, thereby brings into play efficient Hematopoietic Regulation.External report thinks that IL-11 level and platelet are negative feedback regulatory mechanism, and IL-11 is except the adjusting based on periphery platelet count, also by different inflammatory mediators, is regulated.
Select by experiment and the closely-related technical specification of ITP pathogenesis, part has disclosed ITP mechanism.Result shows Hemopoietic factor IL-3, IL-6, IL-11, TGF-β
1, TPO and ITP morbidity is closely related.This studies discovery, and purpura can be by adjusting the imbalance state of Hemopoietic factor IL-3, IL-6, IL-11, TGF-β 1, TPO, promotes platelet counts and improves platelet function, promotes the links such as bone marrow megakaryocyte maturation and get effect.This important discovery is to development ITP Chinese medicine new theory and instruct clinical have science and practical value, significant to the modern difficult treatment theory of performance Chinese medicine.
TGF-β
1to suppress thrombopoietic Hemopoietic factor.
TPO regulates megakaryocyte proliferation, differentiation, maturation and then forms hematoblastic main positive sex factor, is also that an early stage hemopoietic promotes the factor, can promote Megakaryocytic maturation and hematoblastic generation.The specific stimulation megakaryoblast proliferation and differentiation of energy, promotes megakaryocytic maturation also to produce platelet.Result of study demonstration of the present invention, model group medullary cell TPO level obviously increases, and presents decline in various degree after drug treatment.Positivity acting factor as megakaryocyte growth, supposition may be that the especially original macronucleus of bone marrow megakaryocyte, inmature macronucleus increase the negative regulation effect of having brought into play during due to ITP, when periphery platelet destruction increases and while causing platelet counts to decline, Significance of Megakaryocyte Number amount compensatory increases, TPO is discharged in blood, causes the concentration of medullary cell TPO obviously to increase.This is consistent with domestic and foreign literature report.
The multiformity relation of the multifarious group effect of Chinese medicine ingredients and cytokine secretion, from ImmunopharmacologicaResearch angle, may to be them regulate sex material base according to functional status in body different being to the included Multiple components of Chinese medicine itself, and rely this always trend within returning to physiological equilibrium from pathological state; And can, by each ingredient in cytokine network, improve on the whole the immunologic function of body.The whole concept system that this and the traditional Chinese medical science are traditional is perfectly in harmony, and being therefore devoted to Chinese medicine seems very necessary to the research of cytokine regulating action.
The specific embodiment
The following example is in order to further illustrate the present invention, rather than will limit its scope.
Embodiment 1
Respectively by Radix Pseudostellariae 20g, Radix Et Rhizoma Rhei 10g, Rhizoma Chuanxiong 10g, Periostracum Cicadae 10g, Flos Sophorae 15g, Radix Rehmanniae 20g, Radix Paeoniae Alba 20g, Rhizoma Imperatae 15g, Colla Corii Asini 25g, Radix Angelicae Sinensis 10g, Radix Saposhnikoviae 10g, Radix Glycyrrhizae 15g is mixed and controls ITP Chinese medicine.
Embodiment 2
Respectively by Radix Pseudostellariae 5g, Radix Et Rhizoma Rhei 1g, Rhizoma Chuanxiong 4g, Periostracum Cicadae 2g, Flos Sophorae 5g, Radix Rehmanniae 2g, Radix Paeoniae Alba 6g, Rhizoma Imperatae 5g, Colla Corii Asini 10g, Radix Angelicae Sinensis 4g, Radix Saposhnikoviae 3g, Radix Glycyrrhizae 5g is mixed and controls ITP Chinese medicine.
Embodiment 3
Respectively by Radix Pseudostellariae 40g, Radix Et Rhizoma Rhei 30g, Rhizoma Chuanxiong 35g, Periostracum Cicadae 35g, Flos Sophorae 40g, Radix Rehmanniae 50g, Radix Paeoniae Alba 45g, Rhizoma Imperatae 30g, Colla Corii Asini 45g, Radix Angelicae Sinensis 36g, Radix Saposhnikoviae 33g, Radix Glycyrrhizae 34g is mixed and controls ITP Chinese medicine.
Embodiment 4
84 SPF level BLAB/c mices are divided into 7 groups by peripheral blood platelet number, i.e. normal group, model group, Chinese medicine matched group 1(weixuening), the U.S. peace of Chinese medicine matched group 2(blood), control ITP Chinese medicine high dose group (formula of embodiment 1), control dosage group in ITP Chinese medicine (formula of embodiment 1), control ITP Chinese medicine low dose group (formula of embodiment 1).Every group 12.By the variation of ITP model mice peripheral blood platelet number, investigate the effect intensity that treatment Chinese medicine is intervened ITP, by Hemopoietic factor IL-3, IL-6, IL-11, TGF-β 1, TPO changes of contents, investigate the Pharmacodynamical mechanism that treatment Chinese medicine is intervened ITP.
This is studied real result and shows, with normal group comparatively speaking, model group mouse peripheral blood platelet number obviously declines, except weixuening group, each administration group all has the effect that promotes in various degree platelet count.Controlling dosage group lifting peripheral blood platelet number aspect in ITP Chinese medicine (purpura granule) is obviously better than weixuening group, the U.S. peace group of blood, controls ITP Chinese medicine high and low dose group.
Early-stage Study shows that prednisolone acetate fast lifting peripheral blood platelet number aspect is better than purpura granule, but along with the prolongation of administration time, platelet count has downward trend, illustrate that its ascending Platelet has the tendency weakening, also the short term effect that reflects hormone is better, and late result is poor.But in purpura granule three groups, promote the speed of platelet count not as prednisone, but along with the prolongation of time, promote that hematoblastic curative effect obviously strengthens and the persistent period is long, without the advantage of obvious side effect.Because chronic ITP has outbreak tendency repeatedly, prolonged application hormone has obvious side effect, and late result is undesirable, and Chinese Herbs is stable, without significantly side effect, not only can improve number of platelets, also can improve platelet function, obviously improve bleeding.
Table 1ITP mouse peripheral blood platelet number (
, K/ μ l)
Note: with normal group comparison,
★p<0.05; With model group comparison,
▲p<0.05; Contrast 1 weixuening group comparison with Chinese medicine,
■p<0.05; Contrast the comparison of the U.S. peace group of 2 blood with Chinese medicine,
●p<0.05; Between each treatment group, compare,
1) 2) 3)p<0.05
Table 2 respectively organize mouse bone marrow cells IL-3, IL-6, IL-11 concentration comparison (
, ng/L, n=8)
Note: with normal group comparison,
★p<0.05; With model group comparison,
▲p<0.05; With the comparison of Chinese medicine matched group,
■p<0.05
Table 3 is respectively organized mouse bone marrow cells TGF-β
1, TPO concentration comparison (
, ng/L, n=8)
Note: with normal group comparison,
★p<0.05; With model group comparison,
▲p<0.05; With the comparison of Chinese medicine matched group,
■p<0.05
As shown in Table 1, model group and normal group comparison, ITP mouse peripheral blood platelet number obviously declines, and except weixuening group, each administration group all has the effect that promotes in various degree platelet count.The middle dosage group of controlling ITP Chinese medicine promotes peripheral blood platelet number aspect and is obviously better than weixuening group, the U.S. peace group of blood, controls ITP Chinese medicine high and low dose group.
From table 2,3, model group medullary cell IL-3, IL-11 concentration compared with normal group obviously raise, to medullary cell IL-3, IL-11, TPO concentration after ITP treatment, raise, supposition may be because peripheral blood platelet number declines, stimulated medullary cell increment, thereby made medullary cell secretion discharge IL-3, IL-11, the increase of TPO concentration.ITP model blood serum IL-6 concentration compared with normal obviously raises, and to blood serum IL-6 concentration after controlling ITP Chinese medicine, obviously declines, and clinical research raises while finding ITP recurrence once again, shows the state of an illness weight of ITP of IL-6 height.TGF-β
1there is inhibition hemoposieis, ITP model group medullary cell TGF-β
1level obviously increases, and presents decline in various degree after drug treatment, alleviates TGF-β
1suppress hemoposieis.
Studies show that, IL-3, IL-6, IL-11, TGF-β 1, TPO and ITP morbidity are closely related, have participated in this sick immunoreation.Show, purpura side has the effect of obvious lifting ITP model mice peripheral blood platelet number simultaneously, infers that it may be to reach " enrich blood, hemostasis, blood stasis dispelling " effect by the regulation and control megalokaryocyte Hemopoietic factor different with thrombocytopoiesis.
Select by experiment and the closely-related technical specification of ITP pathogenesis, part has disclosed ITP mechanism.Result shows Hemopoietic factor IL-3, IL-6, IL-11, TGF-β
1, TPO and ITP morbidity is closely related.This studies discovery, and purpura can be by adjusting the imbalance state of Hemopoietic factor IL-3, IL-6, IL-11, TGF-β 1, TPO, promotes platelet counts and improves platelet function, promotes the links such as bone marrow megakaryocyte maturation and get effect.This important discovery is to development ITP Chinese medicine new theory and instruct clinical have science and practical value, significant to the modern difficult treatment theory of performance Chinese medicine.
Claims (4)
1. a Chinese medicine for the treatment of immunologic thrombocytopenic purpura, is characterized in that: this ingredients is as follows: Radix Pseudostellariae 40g, Radix Et Rhizoma Rhei 30g, Rhizoma Chuanxiong 35g, Periostracum Cicadae 35g, Flos Sophorae 40g, Radix Rehmanniae 50g, Radix Paeoniae Alba 45g, Rhizoma Imperatae 30g, Colla Corii Asini 45g, Radix Angelicae Sinensis 36g, Radix Saposhnikoviae 33g, Radix Glycyrrhizae 34g.
2. a Chinese medicine for the treatment of immunologic thrombocytopenic purpura, is characterized in that: this ingredients is as follows: Radix Pseudostellariae 5g, Radix Et Rhizoma Rhei 1g, Rhizoma Chuanxiong 4g, Periostracum Cicadae 2g, Flos Sophorae 5g, Radix Rehmanniae 2g, Radix Paeoniae Alba 6g, Rhizoma Imperatae 5g, Colla Corii Asini 10g, Radix Angelicae Sinensis 4g, Radix Saposhnikoviae 3g, Radix Glycyrrhizae 5g.
3. a Chinese medicine for the treatment of immunologic thrombocytopenic purpura, is characterized in that: this ingredients is as follows: Radix Pseudostellariae 20g, Radix Et Rhizoma Rhei 10g, Rhizoma Chuanxiong 10g, Periostracum Cicadae 10g, Flos Sophorae 15g, Radix Rehmanniae 20g, Radix Paeoniae Alba 20g, Rhizoma Imperatae 15g, Colla Corii Asini 25g, Radix Angelicae Sinensis 10g, Radix Saposhnikoviae 10g, Radix Glycyrrhizae 15g.
4. according to the Chinese medicine of one of any described treatment immunologic thrombocytopenic purpura of claim 1-3, it is characterized in that: described Radix Et Rhizoma Rhei is processed with wine processed product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210072570.2A CN102526539B (en) | 2012-03-19 | 2012-03-19 | Traditional Chinese medicinal compound for treating idiopatic thrombocytopenic purpura (ITP) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210072570.2A CN102526539B (en) | 2012-03-19 | 2012-03-19 | Traditional Chinese medicinal compound for treating idiopatic thrombocytopenic purpura (ITP) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102526539A CN102526539A (en) | 2012-07-04 |
| CN102526539B true CN102526539B (en) | 2014-04-09 |
Family
ID=46335359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210072570.2A Active CN102526539B (en) | 2012-03-19 | 2012-03-19 | Traditional Chinese medicinal compound for treating idiopatic thrombocytopenic purpura (ITP) |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102526539B (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1089600C (en) * | 1998-09-28 | 2002-08-28 | 贾秀山 | Medicine for treating leukemia and its preparing process |
| CN1270757C (en) * | 2002-07-12 | 2006-08-23 | 刘光跃 | Chinese traditional medicine for treating purpuric disease and method for making the same |
| CN101015607A (en) * | 2006-12-27 | 2007-08-15 | 辽宁中医药大学 | Traditional Chinese medicine for treating immune thrombocytopenic purpura and preparing method thereof |
-
2012
- 2012-03-19 CN CN201210072570.2A patent/CN102526539B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102526539A (en) | 2012-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102614387A (en) | Traditional Chinese medicine for prevention and treatment of stroke and preparation method thereof | |
| CN101015607A (en) | Traditional Chinese medicine for treating immune thrombocytopenic purpura and preparing method thereof | |
| CN105311219A (en) | Health Jieyu Ningshen mixture | |
| CN103705705A (en) | Traditional Chinese medicine composition for treating polymyositis | |
| CN102526487B (en) | Chinese medicament for treating immune thrombocytopenic purpura | |
| CN108853433A (en) | A kind of Chinese medicine and preparation method thereof for treating diabetic nephropathy | |
| CN102526539B (en) | Traditional Chinese medicinal compound for treating idiopatic thrombocytopenic purpura (ITP) | |
| CN102423335B (en) | Medicine combination for treating impotence and premature ejaculation and preparation method thereof | |
| CN104491810B (en) | A kind of Chinese medicine for treating AIDS deficiency of qi and blood and damp and hot ailment said due to cold or exposure card | |
| CN101474254A (en) | Chinese medicinal composition for treating chronic hepatitis B and preparation method thereof | |
| CN103446272A (en) | Composition for improving sleep, and preparation method and use thereof | |
| CN101214289A (en) | Chinese medicinal composition for treating thrombocytopenic purpura and preparation thereof | |
| CN103520646B (en) | Chinese medicine composition for treating depression and preparation method of Chinese medicine composition | |
| CN102813764A (en) | Chinese herbal medicinal composition used for reducing blood viscosity and blood lipid and preparation method thereof | |
| CN105056049B (en) | It is a kind of to treat phthisical pharmaceutical composition | |
| CN104000987A (en) | Traditional Chinese medicine composition for treating postnatal depression | |
| CN103585449A (en) | Traditional Chinese medicine composition for treating migraine | |
| CN102920836A (en) | Traditional Chinese medicine composite for treating immune thrombocytopenic purpura | |
| CN103007237B (en) | Medicine for treating idiopathic thrombocytopenic purpura (ITP) | |
| CN104940516A (en) | Traditional Chinese medicine composition for treating chronic aplastic anemia, and preparation method and application thereof | |
| CN106138514A (en) | A kind of Chinese medicine composition treating intermingled phlegm and blood stasis type hypertension and preparation method thereof | |
| CN103816392B (en) | Pharmaceutical composition of a kind for the treatment of organs fibrosis and its production and use | |
| CN102727633A (en) | Pharmaceutical composition for treating chronic hepatitis B and preparation method and application thereof | |
| CN101979057A (en) | Medicine for treating anaphylactoid purpura and preparation method thereof | |
| CN107441219B (en) | Pharmaceutical composition for improving immune function of acquired immune deficiency syndrome and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |